Table 1.
Patient and tumor characteristics for the study cohort (having both magnetic resonance imaging (MRI) and mRNA data), MRI validation cohort, and mRNA validation cohort.
| Variables | Study Cohort (n = 95) | MRI Validation Cohort (n = 82) | mRNA Validation Cohort (n = 161) | p-Value * |
|---|---|---|---|---|
| Age, median (range) years | 68 (41–93) | 66 (41–84) | 66 (38–93) | 0.60 |
| FIGO stage | 0.64 | |||
| I–II | 82 (86%) | 68 (83%) | 122 (76%) | |
| III–IV | 13 (14%) | 14 (17%) | 39 (24%) | |
| Histologic subtype | 0.90 | |||
| Endometrioid | 76 (80%) | 65 (79%) | 127 (79%) | |
| Non-endometrioid | 19 (20%) | 17 (21%) | 34 (21%) | |
| Histologic grade § | 0.58 | |||
| Grade 1 | 34 (45%) | 30 (46%) | 44 (35%) | |
| Grade 2 | 21 (28%) | 24 (37%) | 49 (39%) | |
| Grade 3 | 20 (26%) | 10 (15%) | 30 (24%) | |
| ND | 1 (1%) | 1 (2%) | 3 (2%) | |
| Myometrial invasion | 0.04 | |||
| <50% | 47 (50%) | 52 (63%) | 77 (48%) | |
| ≥50% | 48 (50%) | 28 (34%) | 82 (51%) | |
| ND | 2 (3%) | 2 (1%) | ||
| Lymph node metastases | 0.69 | |||
| No | 76 (81%) | 56 (68%) | 92 (57%) | |
| Yes | 10 (10%) | 9 (11%) | 23 (14%) | |
| ND | 9 (9%) | 17 (21%) | 46 (29%) |
* Pearson’s chi-square test for categorical variables and Mann–Whitney U test for continuous variables; § endometroid only; FIGO: The International Federation of Gynecology and Obstetrics; ND, not determined.